SARS vaccine development.
Identifieur interne : 002641 ( PubMed/Curation ); précédent : 002640; suivant : 002642SARS vaccine development.
Auteurs : Shibo Jiang [États-Unis] ; Yuxian He ; Shuwen LiuSource :
- Emerging infectious diseases [ 1080-6040 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical : Epitopes, Spike Glycoprotein, Coronavirus, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Humans.
Abstract
Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.
DOI: 10.3201/1107.050219
PubMed: 16022774
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002641
Links to Exploration step
pubmed:16022774Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS vaccine development.</title>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Blood Center, New York, New York 10021</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
</author>
<author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16022774</idno>
<idno type="pmid">16022774</idno>
<idno type="doi">10.3201/1107.050219</idno>
<idno type="wicri:Area/PubMed/Corpus">002641</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002641</idno>
<idno type="wicri:Area/PubMed/Curation">002641</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002641</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS vaccine development.</title>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Blood Center, New York, New York 10021</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
</author>
<author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="ISSN">1080-6040</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Epitopes</term>
<term>Humans</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Inactivated</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Epitopes</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
<term>Épitopes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16022774</PMID>
<DateCompleted><Year>2005</Year>
<Month>08</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN>
<JournalIssue CitedMedium="Print"><Volume>11</Volume>
<Issue>7</Issue>
<PubDate><Year>2005</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS vaccine development.</ArticleTitle>
<Pagination><MedlinePgn>1016-20</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Yuxian</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Shuwen</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>39</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId>
<ArticleId IdType="pmc">PMC3371787</ArticleId>
<ArticleId IdType="doi">10.3201/1107.050219</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Mar;79(6):3289-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15731223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Mar;79(6):3401-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Mar 30;334(1):134-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 3;361(9368):1519-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12737864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2003 Dec 12;115(6):652-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14675530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jan 30;314(1):235-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14715271</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jan 10;363(9403):99-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14726162</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Genomics. 2004 Jul 8;18(2):245-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15161967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1991 Dec 1;174(6):1557-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1836013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1993 Apr;74 ( Pt 4):745-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7682252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Nov 19;279(47):49414-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15345712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Feb;79(3):1906-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650214</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002641 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002641 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:16022774 |texte= SARS vaccine development. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16022774" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |